ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,482.87
0.09%
Dow Jones
39,164.06
0.09%
US Dollar vs MXN
18.48715
0.28%
Brent Oil
85.695
0.33%
Bitcoin
61,473.48
-0.22%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Verona Pharma Plc (VRNA)

  7. Verona Pharma Plc (VRNA) Noticias

VRNA Verona Pharma Plc

15.15
0.46 (3.13%)
27 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Verona Pharma Plc VRNA NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.46 3.13% 15.15 18:56:11
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
14.80 14.59 16.06 15.44 14.69
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
26/6/202415:57GLOBEVerona Pharma Announces US FDA Approval of Ohtuvayre™..
10/5/202408:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/5/202407:53EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/5/202406:22EDGAR2Form 8-K - Current report
09/5/202406:18EDGAR2Form 8-K - Current report
09/5/202406:15GLOBEVerona Pharma Reports First Quarter 2024 Financial Results..
09/5/202406:00GLOBEVerona Pharma Announces $650 Million Strategic..
02/5/202401:00GLOBEVerona Pharma to Present Additional Analyses of Positive..
25/4/202401:00GLOBEVerona Pharma to Report First Quarter 2024 Financial Results..
08/3/202415:18EDGAR2Form PRE 14A - Other preliminary proxy statements
07/3/202420:40EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/3/202401:00GLOBEAndrew Fisher Joins Verona Pharma as General Counsel
29/2/202408:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202405:08EDGAR2Form 8-K - Current report
29/2/202401:00GLOBEVerona Pharma Reports Fourth Quarter and Full Year 2023..
15/2/202401:00GLOBEVerona Pharma to Report Fourth Quarter and Full Year 2023..
05/2/202417:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202417:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202415:19EDGAR2Form 144 - Report of proposed sale of securities
02/2/202405:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202405:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/2/202405:02EDGAR2Form 8-K - Current report
01/2/202401:00GLOBEMichael Austwick Joins Verona Pharma as Non-Executive..
03/1/202401:00GLOBEVerona Pharma to Present at 42nd Annual J.P. Morgan..
02/1/202405:02EDGAR2Form 8-K - Current report
02/1/202401:00GLOBEVerona Pharma enters into Debt Facility of up to $400..
18/12/202315:15EDGAR2Form 8-K - Current report
17/11/202301:00GLOBEVerona Pharma’s President and CEO David Zaccardelli Wins..
08/11/202301:00GLOBEVerona Pharma Announces November 2023 Investor Conference..
03/11/202319:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202319:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202315:25EDGAR2Form 144 - Report of proposed sale of securities
02/11/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202305:24EDGAR2Form 8-K - Current report
02/11/202302:04GLOBEVerona Pharma Reports Third Quarter 2023 Financial Results..
24/10/202315:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202315:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/10/202301:00GLOBEVerona Pharma to Report Third Quarter 2023 Financial Results..
06/10/202301:00GLOBEVerona Pharma to Host Investor Update on Commercialization..
03/10/202301:00GLOBEVerona Pharma to Present Additional Analyses of Positive..
11/9/202305:02EDGAR2Form 8-K - Current report
11/9/202301:00GLOBEVerona Pharma Announces the US FDA has Accepted the New Drug..
06/9/202301:00GLOBEVerona Pharma to Present Additional Analysis of Phase 3..
05/9/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202315:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
01/9/202315:05EDGAR2Form 8-K - Current report
31/8/202301:00GLOBEChristina Ackermann Joins Verona Pharma as Non-Executive..
07/8/202320:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/8/202320:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202319:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
VRNA
Verona Pharma
BOV
EUCA4F
EUCATEX PN
BOV
ODPV3F
ODONTOPREV ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados